» Articles » PMID: 38420354

Inflammation Mechanism and Anti-inflammatory Therapy of Dry Eye

Overview
Specialty General Medicine
Date 2024 Feb 29
PMID 38420354
Authors
Affiliations
Soon will be listed here.
Abstract

Dry eye is a widespread chronic inflammatory disease that causes fatigue, tingling, burning, and other symptoms. Dry eye is attributed to rheumatic diseases, diabetes, hormone disorders, and contact lenses, which activate inflammatory pathways: mitogen-activated protein kinases (MAPK) and nuclear factor-B (NF-κB), promote macrophage inflammatory cell and T cell activation, and inflammation factors. Clinicians use a combination of anti-inflammatory drugs to manage different symptoms of dry eye; some of these anti-inflammatory drugs are being developed. This review introduces the dry eye inflammation mechanisms and the involved inflammatory factors. We also elucidate the anti-inflammatory drug mechanism and the detection limits.

Citing Articles

Recalcitrant Dry Eye Disease in a 31-Year-Old Female: Favorable Outcomes Following Complete Ocular Lavage Facilitated by an Irrigating Eyelid Retractor.

Maiti S, Kondapalli S, Periman L Cureus. 2025; 17(2):e78554.

PMID: 40062090 PMC: 11887804. DOI: 10.7759/cureus.78554.


Role of Chinese Medicine Monomers in Dry Eye Disease: Breaking the Vicious Cycle of Inflammation.

Hu Z, Chen X, Hu Q, Zou M, Liu Z Pharmacol Res Perspect. 2025; 13(2):e70077.

PMID: 39979080 PMC: 11842162. DOI: 10.1002/prp2.70077.


Corneal protective effects of a new ophthalmic formulation based on vitamin B12 and sodium hyaluronate.

Lazzara F, Conti F, Maugeri G, DAgata V, Sotera L, Bucolo C Front Pharmacol. 2025; 16:1548213.

PMID: 39959421 PMC: 11826061. DOI: 10.3389/fphar.2025.1548213.


Therapeutic benefits of glycerol in dry eye disease.

Ronderos V, Bollag W Front Med (Lausanne). 2025; 11:1531670.

PMID: 39882517 PMC: 11774691. DOI: 10.3389/fmed.2024.1531670.


Molecular mechanisms of Buqing granule for the treatment of diabetic retinopathy: Network pharmacology analysis and experimental validation.

Yang Y, Yuan L, Li X, Liu Q, Jiang W, Jiao T World J Diabetes. 2024; 15(9):1942-1961.

PMID: 39280184 PMC: 11372640. DOI: 10.4239/wjd.v15.i9.1942.


References
1.
Luo L, Li D, Doshi A, Farley W, Corrales R, Pflugfelder S . Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. Invest Ophthalmol Vis Sci. 2004; 45(12):4293-301. DOI: 10.1167/iovs.03-1145. View

2.
Ellenberg D, Azar D, Hallak J, Tobaigy F, Han K, Jain S . Novel aspects of corneal angiogenic and lymphangiogenic privilege. Prog Retin Eye Res. 2010; 29(3):208-48. PMC: 3685179. DOI: 10.1016/j.preteyeres.2010.01.002. View

3.
McCabe E, Narayanan S . Advancements in anti-inflammatory therapy for dry eye syndrome. Optometry. 2009; 80(10):555-66. DOI: 10.1016/j.optm.2009.02.010. View

4.
Farrand K, Fridman M, Ozer Stillman I, Schaumberg D . Prevalence of Diagnosed Dry Eye Disease in the United States Among Adults Aged 18 Years and Older. Am J Ophthalmol. 2017; 182:90-98. DOI: 10.1016/j.ajo.2017.06.033. View

5.
Raizman M . Corticosteroid therapy of eye disease. Fifty years later. Arch Ophthalmol. 1996; 114(8):1000-1. DOI: 10.1001/archopht.1996.01100140208016. View